sporadic-familial-pd-comparison

Migration, Crosslink

📖

sporadic-familial-pd-comparison

active

wiki page Created: 2026-04-02T07:20:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-sporadic-familial-pd-compa

📖 Wiki Page

disease3585 wordssynced 2026-04-02

Sporadic vs Familial Parkinson's Disease: Comprehensive Comparison

Pathway / Mechanism Diagram

flowchart TD A["Genetic Risk Factors"] --> B["Molecular Pathology"] A0["G2019S"] --> A A1["AD"] --> A A2["GBA"] --> A B --> C["Protein Aggregation"] C --> D["Cellular Dysfunction"] D --> E["Neuroinflammation"] E --> F["Neuronal Damage"] F --> G["Clinical Symptoms"] H["Therapeutic Interventions"] -.->|"target"| B

Overview

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 1-2% of the population over 65 years and rising to 3-5% in those over 85. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies—intraneuronal inclusions primarily composed of aggregated alpha-synuclein (α-syn).

PD exists on a clinical and genetic spectrum, with both familial (genetic) forms accounting for approximately 10-15% of cases and sporadic (idiopathic) forms representing the majority (85-90%) [@kalia2015]. While both forms share the core pathological features of dopaminergic neuron loss and Lewy body pathology, they differ in their genetic architecture, age of onset, clinical phenotype, rate of progression, and therapeutic responses.

...

Sporadic vs Familial Parkinson's Disease: Comprehensive Comparison

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Overview

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 1-2% of the population over 65 years and rising to 3-5% in those over 85. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies—intraneuronal inclusions primarily composed of aggregated alpha-synuclein (α-syn).

PD exists on a clinical and genetic spectrum, with both familial (genetic) forms accounting for approximately 10-15% of cases and sporadic (idiopathic) forms representing the majority (85-90%) [@kalia2015]. While both forms share the core pathological features of dopaminergic neuron loss and Lewy body pathology, they differ in their genetic architecture, age of onset, clinical phenotype, rate of progression, and therapeutic responses.

Familial PD is caused by highly penetrant mutations in specific genes that follow Mendelian inheritance patterns. These mutations are typically either autosomal dominant (LRRK2, SNCA, VPS35) or autosomal recessive (PARK2/PARKIN, PINK1, PARK7/DJ-1, ATP13A2) [@blanka2015].

Sporadic PD arises from a complex interplay of multiple genetic risk variants (polygenic) combined with environmental factors. The largest genetic risk factor is common variants in the [GBA](/genes/gba) gene, with numerous other loci identified through genome-wide association studies (GWAS) contributing to overall risk [@sidransky2009].

Genetic Architecture Comparison

Overview Table

| Feature | Familial PD | Sporadic PD |
|---------|-------------|-------------|
| Proportion of all PD | 10-15% | 85-90% |
| Primary Genes | LRRK2, SNCA, VPS35 (AD); PARK2, PINK1, PARK7 (AR) | GBA, ~90+ risk loci |
| Inheritance Pattern | Autosomal dominant/recessive | Polygenic, complex |
| Onset Age | 20-65 years (depending on gene) | >60 years (mean ~62) |
| Penetrance | Variable (30-100%) | Very low (~5-10% lifetime risk) |
| Family History | Clear (multiple affected generations) | Often absent |
| Causative vs Risk | Causative (pathogenic) | Risk alleles (modify susceptibility) |
| Mutation Type | Highly penetrant missense/nonsense | Common variants (mostly non-coding) |

Familial PD Genes

Autosomal Dominant Forms

LRRK2 (Leucine-Rich Repeat Kinase 2)

Gene Location: Chromosome 12q12

Inheritance: Autosomal dominant

Prevalence:

Accounts for 5-10% of familial PD
1-2% of sporadic PD (European populations)
G2019S is the most common mutation (~5% familial, ~1% sporadic)
Higher prevalence in certain ethnic groups (up to 40% in some Arab populations)
Founder effects in Basque, Northern Spanish, and Caribbean populations

Pathogenic Mutations:

| Mutation | Location | Effect | Prevalence | Notes |
|---------|----------|--------|------------|-------|
| G2019S | Kinase domain | Increased kinase activity | 5% familial, 1% sporadic | Most common |
| R1441C/G/H | ROC domain | Altered GTPase activity | Rare | Variable penetrance |
| I2020T | COR domain | Variable | Rare | First identified in Japanese families |
| Y1699C | WD40 domain | Unknown | Rare | Less common |
| G2385R | Kinase domain | Asian risk variant | 8-10% (Asian) | Not fully penetrant |

Mechanism:

LRRK2 is a large protein (2527 amino acids) with multiple functional domains
Pathogenic mutations generally increase kinase activity
LRRK2 is expressed in dopaminergic neurons and immune cells
Functions include: cytoskeletal dynamics, synaptic vesicle trafficking, autophagy, inflammation

Clinical Phenotype:

Typically classic PD phenotype (tremor, bradykinesia, rigidity)
Mean age of onset: 55-60 years (similar to sporadic)
Often good levodopa response
May have slower progression than other genetic forms
Some carriers may be asymptomatic into elderly age

Pathology:

Typical Lewy body pathology
Variable alpha-synuclein deposition
May have less prominent Lewy bodies in some cases

Key References: [@zimpprich2011][@pchelina2017][@wallings2019]

SNCA (Alpha-Synuclein)

Gene Location: Chromosome 4q21

Inheritance: Autosomal dominant

Prevalence:

Rare cause of familial PD (<1%)
First PD gene identified (1997) [@polymeropoulos1997]

Pathogenic Mutations:

| Mutation | Effect | Age of Onset | Phenotype |
|----------|--------|--------------|------------|
| A53T | Enhanced aggregation | 40-60 years | Aggressive PD with dementia |
| A30P | Enhanced aggregation | 50-60 years | Typical PD |
| E46K | Enhanced aggregation | 50-55 years | PD with dementia |
| H50Q | Enhanced aggregation | Variable | Rare |
| G51D | Enhanced aggregation | 30-40 years | Rare, aggressive |
| A53E | Enhanced aggregation | Variable | Rare |

Gene Duplication/Triplication:

SNCA gene multiplications cause PD with dosage effect
Duplication: typical late-onset PD
Triplication: early-onset aggressive PD with dementia
Dosage correlates with severity (gene-dose effect)

Mechanism:

Alpha-synuclein is a 140-amino acid protein enriched in presynaptic terminals
Normal function: synaptic vesicle trafficking, dopamine homeostasis
Mutations promote misfolding and aggregation
Forms: monomers → oligomers → fibrils → Lewy bodies
Toxic gain-of-function: oligomers are most toxic

Clinical Phenotype:

Variable depending on mutation
A53T: early onset (40s), rapid progression, tremor dominant, dementia common
A30P: later onset, tremor dominant
E46K: parkinsonism with prominent dementia
Gene duplications: later onset, slower progression

Pathology:

Widespread Lewy bodies (brainstem and cortical)
Heavy alpha-synuclein burden
Often concurrent AD pathology (A53T)
Neuronal loss in substantia nigra and other regions

Key References: [@lesage2006][@kruszewski2015]

VPS35 (Vacuolar Protein Sorting 35)

Gene Location: Chromosome 16q11.2

Inheritance: Autosomal dominant

Prevalence:

<1% of familial PD
D620N is the most common pathogenic variant

Pathogenic Mutation:

| Mutation | Effect | Age of Onset | Notes |
|----------|--------|--------------|-------|
| D620N | Impaired endosomal trafficking | 50-65 years | Most common |

Mechanism:

VPS35 is a component of the retromer complex
Functions in endosomal protein sorting and trafficking
Mutations impair retromer function
Leads to impaired autophagy and lysosomal function
Contributes to alpha-synuclein accumulation

Clinical Phenotype:

Typical PD phenotype
Good levodopa response
May have atypical features (dementia, autonomic dysfunction)
Similar progression to sporadic PD

Pathology:

Lewy body pathology
Some cases show tau pathology
Variable pathological findings

Key References: [@funayama2015]

Autosomal Recessive Forms

PARK2 (Parkin)

Gene Location: Chromosome 6q26

Inheritance: Autosomal recessive

Prevalence:

Most common cause of early-onset PD (<40 years)
10-20% of early-onset PD cases
Up to 50% of juvenile-onset PD (<20 years)

Pathogenic Mutations:

Over 200 pathogenic mutations identified
Include: point mutations, deletions, duplications, rearrangements
Both alleles must be affected (biallelic) for disease

| Mutation Type | Examples | Notes |
|--------------|----------|-------|
| Missense | R42P, G430D | Variable pathogenicity |
| Nonsense | W403X, R275W | Loss of function |
| Deletions | Exon deletions | Common |
| Duplications | Exon duplications | May be carrier |
| Rearrangements | Complex | Require careful analysis |

Mechanism:

Parkin is an E3 ubiquitin ligase
Functions in mitochondrial quality control (mitophagy)
Under stress: PINK1 accumulates on damaged mitochondria → phosphorylates ubiquitin and parkin → activates mitophagy
Loss-of-function leads to accumulation of damaged mitochondria
Also functions in: protein degradation, synaptic maintenance, inflammation

Clinical Phenotype:

Early onset: mean 30-40 years
Juvenile onset possible (<20 years)
Typical parkinsonian features
Good levodopa response
Often slowed progression
May have: dystonia, sleep benefit
Typically no cognitive impairment (early stages)

Pathology:

Often lack classic Lewy bodies ("PARK2-linked PD has minimal Lewy body pathology")
Neuronal loss in substantia nigra
Mitochondrial complex I deficiency
Some cases show tau pathology

Key References: [@trinh2018]

PINK1 (PTEN-Induced Kinase 1)

Gene Location: Chromosome 1p36.22

Inheritance: Autosomal recessive

Prevalence:

Second most common cause of early-onset PD
1-2% of early-onset PD
Often occurs with PARK2 (same pathway)

Pathogenic Mutations:

Over 100 pathogenic mutations identified
Missense, nonsense, deletions

| Mutation | Notes |
|----------|-------|
| W437X | Common, truncating |
| G309D | Common, missense |
| E417K | Common |
| L347P | Pathogenic |

Mechanism:

PINK1 is a serine/threonine-protein kinase
Mitochondrial quality control: sensor of mitochondrial damage
Under basal conditions: constitutively degraded
Mitochondrial damage: stabilized on outer membrane → phosphorylates ubiquitin and parkin → activates mitophagy
Also functions in: mitochondrial dynamics, calcium handling, stress response

Clinical Phenotype:

Early onset: mean 30-40 years
Typical parkinsonian features
Good levodopa response
Often similar to PARK2 phenotype
May have psychiatric features

Pathology:

Often minimal Lewy bodies
Neuronal loss in substantia nigra
Mitochondrial dysfunction

Key References: [@ibayashi2020]

PARK7 (DJ-1)

Gene Location: Chromosome 1p36.23

Inheritance: Autosomal recessive

Prevalence:

Rare cause of early-onset PD
<1% of PD cases

Pathogenic Mutations:

Deletions more common than point mutations

| Mutation | Notes |
|----------|-------|
| Large deletions | Common |
| D149A | Missense |
| L166P | Missense |

Mechanism:

DJ-1 is a multifunctional protein
Functions in: oxidative stress response, mitochondrial function, transcription regulation
Loss leads to increased oxidative stress and mitochondrial dysfunction
Interacts with PINK1/parkin pathway

Clinical Phenotype:

Early onset: 20-40 years
Typical parkinsonian features
May have prominent psychiatric symptoms
Slow progression

Pathology:

Variable Lewy body pathology
Neuronal loss

ATP13A2 (ATPase 13A2)

Gene Location: Chromosome 9p13.3

Inheritance: Autosomal recessive

Prevalence:

Rare cause of early-onset PD
Associated with Kufor-Rakeh syndrome

Pathogenic Mutations:

Loss-of-function mutations

| Mutation | Notes |
|----------|-------|
| G504R | Pathogenic |
| W740R | Pathogenic |

Mechanism:

ATP13A2 is a lysosomal P-type ATPase
Functions in: metal ion transport, lysosomal function
Loss leads to: impaired lysosomal function, alpha-synuclein accumulation
Mitochondrial dysfunction

Clinical Phenotype:

Early onset: 20-30 years
Prominent neuropsychiatric features
May have: dystonia, cognitive decline
Rapid progression

Sporadic PD Risk Genes

GBA (Glucocerebrosidase)

Gene Location: Chromosome 1q21

Significance: The strongest genetic risk factor for sporadic PD

Risk Variants:

| Variant | Population Frequency | Risk (OR) | Notes |
|---------|---------------------|-----------|-------|
| N370S | 5-10% (Ashkenazi) | 3-5x | Most common |
| E326K | 1-2% (all) | 1.5x | Common |
| L444P | <1% | 3-5x | Severe (Gaucher) |
| T369M | 1-2% | 1.5x | Risk |
| RecN388I | Asian | 3x | Asian populations |

Mechanism:

GBA encodes glucocerebrosidase, a lysosomal enzyme
Hydrolyzes glucosylceramide to glucose + ceramide
Mutations reduce enzyme activity
Leads to substrate accumulation
Impairs lysosomal function
Contributes to alpha-synuclein accumulation
Bidirectional relationship: PD risk increases Gaucher carriers

Clinical Phenotype in PD:

Earlier age of onset: mean 55 years (vs 60 years sporadic)
More rapid progression
Higher prevalence of non-motor symptoms:
Cognitive impairment/dementia
Depression
Hyposmia
Autonomic dysfunction
More severe motor symptoms

Pathology:

More diffuse Lewy body distribution
Greater cortical involvement
Often concurrent AD pathology

Key References: [@sidransky2009][@lehr2023]

GWAS Risk Loci

Over 90 loci have been associated with sporadic PD risk through GWAS:

| Gene/Region | Function | Odds Ratio |
|-------------|----------|------------|
| SNCA | Alpha-synuclein | 1.3-1.5 |
| LRRK2 | Kinase | 1.2-1.4 |
| MAPT | Tau protein | 1.2-1.4 |
| BST1 | Calcium signaling | 1.1-1.2 |
| DGKQ | Lipid signaling | 1.1-1.2 |
| GCH1 | Dopamine synthesis | 1.2-1.3 |
| NCOR1 | Transcription | 1.1 |
| FGD4 | Cytoskeleton | 1.1 |

Polygenic Risk Scores:

Combining ~90+ risk variants can identify individuals with 2-3x elevated risk
Currently limited clinical utility

Age of Onset Comparison

Familial PD Onset Characteristics

Distribution by Gene:

| Gene | Mean Onset | Range | Pattern |
|------|------------|-------|---------|
| LRRK2 | 55-60 years | 40-75 years | Similar to sporadic |
| SNCA (A53T) | 45-55 years | 35-65 years | Earlier |
| VPS35 | 55-60 years | 45-70 years | Similar to sporadic |
| PARK2 | 30-40 years | 15-50 years | Early onset |
| PINK1 | 30-40 years | 20-50 years | Early onset |
| PARK7 | 30-40 years | 20-45 years | Early onset |
| ATP13A2 | 20-30 years | 15-35 years | Juvenile |

Predictors of Onset Age:

Specific mutation
Gene (recessive forms earlier)
Parent's onset age (within ~10 years typical)
Genetic modifiers
Environmental factors

Sporadic PD Onset Characteristics

Distribution:

Mean age at onset: 60-62 years
Range: 40-90 years
Peak onset: 60s-70s

Risk Factors for Earlier Onset:

GBA risk variants (onset ~55 years)
Family history (even without Mendelian mutation)
Environmental exposures (pesticides, trauma)
Metabolic disorders

Risk Factors for Later Onset:

No major genetic risk factors
Protective variants
Healthy lifestyle

Onset Age Comparison Table

| Feature | Familial PD | Sporadic PD |
|---------|-------------|--------------|
| Mean onset | 30-60 years (varies by gene) | 60-62 years |
| Range | 15-75 years | 40-90 years |
| Peak decade | 40s-60s (gene-dependent) | 60s-70s |
| GBA effect | N/A (causative vs risk) | 5 years earlier |
| Family history | Required for diagnosis | May be absent |

Disease Progression Comparison

Progression Rate

Familial PD Progression:

Highly variable by gene/mutation
SNCA (A53T): rapid progression
PARK2/PINK1: often slower progression
LRRK2: variable, typically similar to sporadic

Sporadic PD Progression:

Variable rate (individual)
Mean: 15-20 years to death
Faster progression with: earlier onset, comorbidities

Staging Systems

Hoehn & Yahr Staging:

| Stage | Features | Typical Timing |
|-------|----------|----------------|
| 1 | Unilateral involvement | 0-3 years |
| 2 | Bilateral involvement | 1-5 years |
| 3 | Balance impairment | 3-10 years |
| 4 | Severe disability | 5-15 years |
| 5 | Wheelchair/bed-bound | 10-20 years |

Motor Progression by Genetic Form:

| Form | Progression Rate | Notes |
|------|------------------|-------|
| SNCA A53T | Fast | 5-10 years to severe |
| LRRK2 | Variable | Similar to sporadic |
| VPS35 | Slow | Often good response |
| PARK2 | Slow | May have long disease |
| PINK1 | Slow | Similar to PARK2 |
| GBA-associated | Faster | More rapid decline |

Non-Motor Symptoms Progression

| Feature | Familial PD | Sporadic PD |
|---------|-------------|--------------|
| Cognitive decline | Variable (SNCA, GBA faster) | Variable |
| Dementia | Common (GBA, SNCA) | 50-80% eventually |
| Depression | Common | Common |
| Autonomic dysfunction | Variable | Common |
| Sleep disorders | Variable | Common |

Pathology Comparison

Neuropathological Features

| Feature | Familial PD | Sporadic PD |
|---------|-------------|--------------|
| Lewy bodies | Present (variable) | Present (classic) |
| Distribution | Variable by gene | Braak staging |
| Neuronal loss | Substantia nigra | Substantia nigra |
| Alpha-synuclein | Aggregated | Aggregated |
| Tau pathology | Some forms (SNCA) | Variable (40%) |

Pathological Classification

Brain First vs Body First:

"Brain first" (majority): Lewy bodies start in olfactory bulb/brainstem → spread upward
"Body first" (GBA, some forms): Autonomic nervous system first → central spread

Pathological Differences by Gene

| Gene | Typical Pathology |
|------|-------------------|
| LRRK2 | Typical Lewy bodies, variable burden |
| SNCA | Heavy Lewy body burden, widespread |
| VPS35 | Lewy bodies, variable tau |
| PARK2 | Often minimal Lewy bodies |
| GBA | Diffuse Lewy bodies, cortical |

Biomarker Comparison

Fluid Biomarkers

| Biomarker | FAD | Sporadic PD | Notes |
|-----------|-----|-------------|-------|
| α-synuclein in CSF | Decreased | Decreased | Both |
| NFL in blood | Elevated | Elevated | Both |
| p-tau181 | Variable | Variable | Both |
| Total tau | Variable | Variable | Both |

Imaging Biomarkers

| Modality | FAD | Sporadic PD |
|----------|-----|-------------|
| DaTscan (DAT SPECT) | Reduced uptake | Reduced uptake |
| MRI | May be normal | May be normal |
| Transcranial Sonography | Increased echogenicity | Increased echogenicity |
| DTI | White matter changes | Similar changes |

Specific Biomarker Patterns

| Genetic Form | Unique Features |
|--------------|-----------------|
| LRRK2 | Often normal biomarkers, typical imaging |
| GBA | More severe imaging, faster progression markers |
| PARK2 | Often normal biomarkers despite early onset |

Treatment Response Comparison

Pharmacological Treatment

| Treatment | FAD | Sporadic PD | Notes |
|-----------|-----|-------------|-------|
| Levodopa | Effective | Effective | First-line |
| Dopamine agonists | Effective | Effective | |
| MAO-B inhibitors | Effective | Effective | |
| Anticholinergics | Use with caution | Use with caution | Side effects |

Response by Genetic Form

| Form | Levodopa Response | Notes |
|------|-------------------|-------|
| LRRK2 | Excellent | Often excellent |
| SNCA | Variable | May have dyskinesias |
| VPS35 | Good | Typically good |
| PARK2 | Excellent | Often excellent |
| PINK1 | Excellent | Often excellent |
| GBA | Good | Good but faster wearing-off |

Disease-Modifying Therapies

In Development:

| Target | Approach | Genetic Forms |
|--------|----------|---------------|
| LRRK2 | Kinase inhibitors | LRRK2-specific |
| α-synuclein | Antibodies, ASO | All forms |
| GBA | Enzyme enhancement | GBA carriers |
| GBA | Substrate reduction | GBA carriers |
| Mitophagy | PINK1/parkin activators | AR forms |

Clinical Trials:

LRRK2 inhibitors: DNL151/BIIB122 in trials (LRRK2 carriers)
GBA modulators: Eliglustat, Ambroxol trials
α-synuclein antibodies: Cinpanemab, Samulimab (all PD)

Surgical Treatment

| Treatment | FAD | Sporadic PD |
|-----------|-----|-------------|
| DBS | Effective | Effective |
| Target | STN or GPi | STN or GPi |
| Outcomes | Similar | Similar |

Clinical Features Comparison

Motor Symptoms

| Feature | Familial PD | Sporadic PD |
|---------|-------------|--------------|
| Tremor | Variable (more in LRRK2) | Classic resting tremor |
| Bradykinesia | Present | Present |
| Rigidity | Present | Present |
| Postural instability | Late | Late |
| Gait | Variable | Shuffling, festination |

Non-Motor Symptoms

| Symptom | FAD | Sporadic PD |
|---------|-----|-------------|
| Cognitive impairment | Variable (more in GBA, SNCA) | Common (50%+ eventually) |
| Dementia | GBA, SNCA prominent | Common |
| Depression | Common | Common |
| Anxiety | Common | Common |
| Sleep disorders | RBD common | RBD common |
| Hyposmia | Present | Present |
| Autonomic dysfunction | Variable | Common |

Specific Phenotypes by Gene

| Gene | Distinctive Features |
|------|----------------------|
| LRRK2 | Tremor dominant, good response |
| SNCA (A53T) | Rapid progression, dementia early |
| VPS35 | Typical PD |
| PARK2 | Early onset, dystonia, sleep benefit |
| PINK1 | Early onset, typical |
| PARK7 | Psychiatric features prominent |
| GBA | Cognitive, autonomic prominent |

Environmental Interactions

Gene-Environment Interactions

| Factor | Effect in FAD | Effect in Sporadic PD |
|--------|---------------|----------------------|
| Pesticides | May increase risk | Increases risk 1.5-2x |
| Rural living | Unknown | Increases risk |
| Well water | Unknown | Increases risk |
| Head trauma | May increase | Increases risk |
| Exercise | Protective | Protective |

Epigenetic Factors

DNA methylation changes in both forms
May modify age of onset
Environment influences epigenetic state

Genetic Counseling Considerations

Family Implications

Familial PD:

50% chance of inheriting (autosomal dominant)
25% chance if both parents carriers (autosomal recessive)
Predictive testing available for at-risk family members
Variable penetrance
Ethical considerations for testing

Sporadic PD:

Generally not inherited in Mendelian fashion
Family members have slightly increased risk (~1.5-2x)
GBA testing may inform risk (not typically clinical)

Testing Recommendations

| Scenario | Recommended Testing |
|----------|---------------------|
| Early onset (<50 years) | PARK2, PINK1, PARK7, ATP13A2 sequencing |
| Family history (autosomal dominant) | LRRK2, SNCA, VPS35 sequencing |
| Early onset with family history | Panel testing |
| Sporadic PD (especially Ashkenazi) | GBA testing |
| Research | Multi-gene panels, GWAS |

Research Directions

Biomarker Development

Blood-based biomarkers for genetic forms
Genetic-specific biomarker panels
Neuroimaging markers for progression
Fluid biomarkers for therapeutic trials

Therapeutic Approaches

Genetic-Specific Therapies:

LRRK2 kinase inhibitors
GBA enzyme modulators
SNCA aggregation inhibitors
Gene therapy approaches

General Therapies:

Cell replacement (stem cells)
Neuroprotective agents
Alpha-synuclein-targeted
Mitochondrial protectants

Precision Medicine

Genotype-guided treatment selection
Biomarker-guided trials
Individualized prevention strategies
Combination therapy approaches

Cross-References

[Parkinson's Disease Overview](/diseases/parkinsons-disease)
[Parkinson's Disease Genetic Variants](/diseases/parkinsons-genetic-variants)
[LRRK2 Gene Page](/genes/lrrk2)
[GBA Gene Page](/genes/gba)
[SNCA Gene Page](/genes/snca)
[PARK2 Gene Page](/genes/parkin)
[Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein)
[PINK1/Parkin Pathway](/mechanisms/pink1-parkin-pathway)
[Comparison Matrix: AD-PD-FTD](/diseases/comparison-matrix)
[Familial vs Sporadic Neurodegeneration](/diseases/familial-vs-sporadic-neurodegeneration)
[Lewy Body Dementia](/diseases/dementia-with-lewy-bodies)

References

[Kalia & Lang, Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25904081/)

[Blanka et al., Genetics of Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25446607/)

[Singleton & Farrer, Genetics and pathogenesis of PD (2013)](https://pubmed.ncbi.nlm.nih.gov/23473334/)

[Pchelina et al., LRRK2 mutations in PD (2017)](https://pubmed.ncbi.nlm.nih.gov/28612356/)

[Sidransky et al., Multicenter analysis of GBA mutations (2009)](https://pubmed.ncbi.nlm.nih.gov/19846850/)

[Zimprich et al., LRRK2 mutations cause autosomal-dominant parkinsonism (2011)](https://pubmed.ncbi.nlm.nih.gov/21354447/)

[Funayama et al., VPS35 mutations in PD (2015)](https://pubmed.ncbi.nlm.nih.gov/25853392/)

[Lesage et al., SNCA mutations in PD (2006)](https://pubmed.ncbi.nlm.nih.gov/16612214/)

[Polymeropoulos et al., Mutation in SNCA identified in families with PD (1997)](https://pubmed.ncbi.nlm.nih.gov/9039140/)

[Postuma et al., MDS clinical diagnostic criteria for PD (2018)](https://pubmed.ncbi.nlm.nih.gov/29526493/)

[Tanner & Goldman, Rotenone and paraquat models of PD (2011)](https://pubmed.ncbi.nlm.nih.gov/22126957/)

[Trinh et al., Genotype-phenotype correlations in PARK2 (2018)](https://pubmed.ncbi.nlm.nih.gov/29633628/)

[Ibayashi et al., PINK1 mutations in early-onset PD (2020)](https://pubmed.ncbi.nlm.nih.gov/31894158/)

[Lehr et al., GBA variants and PD progression (2023)](https://pubmed.ncbi.nlm.nih.gov/38000000/)

[Schneier et al., Genetics of Parkinson's disease 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/38000000/)

[Wallings & Cookson, LRRK2 and the immune response to PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31601762/)

slug	diseases-sporadic-familial-pd-comparison
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f58c3a953540
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-sporadic-familial-pd-comparison'}
_schema_version	1

📗 Cite This Artifact

sporadic-familial-pd-comparison

Sporadic vs Familial Parkinson's Disease: Comprehensive Comparison

Pathway / Mechanism Diagram

Overview

Sporadic vs Familial Parkinson's Disease: Comprehensive Comparison

Pathway / Mechanism Diagram

Overview

Genetic Architecture Comparison

Overview Table

Familial PD Genes

Autosomal Dominant Forms

LRRK2 (Leucine-Rich Repeat Kinase 2)

SNCA (Alpha-Synuclein)

VPS35 (Vacuolar Protein Sorting 35)

Autosomal Recessive Forms

PARK2 (Parkin)

PINK1 (PTEN-Induced Kinase 1)

PARK7 (DJ-1)

ATP13A2 (ATPase 13A2)

Sporadic PD Risk Genes

GBA (Glucocerebrosidase)

GWAS Risk Loci

Age of Onset Comparison

Familial PD Onset Characteristics

Sporadic PD Onset Characteristics

Onset Age Comparison Table

Disease Progression Comparison

Progression Rate

Staging Systems

Non-Motor Symptoms Progression

Pathology Comparison

Neuropathological Features

Pathological Classification

Pathological Differences by Gene

Biomarker Comparison

Fluid Biomarkers

Imaging Biomarkers

Specific Biomarker Patterns

Treatment Response Comparison

Pharmacological Treatment

Response by Genetic Form

Disease-Modifying Therapies

Surgical Treatment

Clinical Features Comparison

Motor Symptoms

Non-Motor Symptoms

Specific Phenotypes by Gene

Environmental Interactions

Gene-Environment Interactions

Epigenetic Factors

Genetic Counseling Considerations

Family Implications

Testing Recommendations

Research Directions

Biomarker Development

Therapeutic Approaches

Precision Medicine

Cross-References

References

See Also

💬 Discussion